Assenagon Asset Management
TVRD

Assenagon Asset Management’s Tvardi Therapeutics TVRD Stock Holding History

Assenagon Asset Management’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-379
Closed -$4.21K – 1468
2024
Q3 		$4.21K Sell
379
-20
-5% -$234 ﹤0.01% 1358
2024
Q2 		$3.7K Sell
399
-4,416
-92% -$105K ﹤0.01% 1403
2024
Q1 		$158K Buy
4,815
+153
+3% +$3.97K ﹤0.01% 1335
2023
Q4 		$125K Buy
4,662
+2,840
+156% +$118K ﹤0.01% 1383
2023
Q3 		$110K Buy
+1,822
New +$171K ﹤0.01% 1354
2023
Q1 		– Sell
-2,821
Closed -$1.09M – 1528
2022
Q4 		$1.09M Buy
2,821
+1,913
+211% +$727K ﹤0.01% 1017
2022
Q3 		$306K Sell
908
-409
-31% -$148K ﹤0.01% 1202
2022
Q2 		$433K Buy
+1,317
New +$462K ﹤0.01% 1252
2021
Q3 		– Sell
-20,334
Closed -$10.4M – 1456
2021
Q2 		$10.4M Buy
20,334
+18,559
+1,046% +$11.8M 0.04% 332
2021
Q1 		$1.39M Buy
1,775
+793
+81% +$543K 0.01% 810
2020
Q4 		$535K Sell
982
-3,582
-78% -$1.88M ﹤0.01% 839
2020
Q3 		$2.09M Buy
+4,564
New +$2.65M 0.01% 573
2020
Q1 		– Sell
-1,728
Closed -$1M – 1035
2019
Q4 		$1M Buy
+1,728
New +$1.21M 0.01% 578

Other funds holding TVRD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Rockefeller Capital Management
Rockefeller Capital Management New York $56.4B AUM 24.96% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CRC
Curi RMB Capital Chicago, Illinois $5.62B AUM 18.93% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Assenagon Asset Management's TVRD Position: Q4 2024 in Review

Assenagon Asset Management sold out of Tvardi Therapeutics (TVRD) in Q4 2024, closing a stake of 379 shares — an estimated $4.21K sold.

Assenagon Asset Management first reported a position in TVRD in Q4 2019 and held it in 13 quarters. The position peaked at $10.4M in Q2 2021. 43 funds tracked by Wall St. Rank hold TVRD as of Q4 2024.

  • Assenagon Asset Management reported no remaining Tvardi Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Assenagon Asset Management sold 379 Tvardi Therapeutics shares in Q4 2024, an estimated $4.21K.
  • Assenagon Asset Management first reported a position in Tvardi Therapeutics in Q4 2019 and held it in 13 quarters.
  • Assenagon Asset Management's Tvardi Therapeutics position peaked at $10.4M in Q2 2021.
  • 43 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q4 2024.

Based on Assenagon Asset Management's 13F filing for Q4 2024, filed 14 Jan 2025.